Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...